I guess the other side of that coin is that you have the European pharmaceutical industry with its rules and patent restrictions and so on. On the other side of us you have the United States, and then you have us in the middle with a different set of rules. Given that complication, I think there is some worry that making certain concessions to the Europeans will drive capital out of Canada and into the U.S. for research in the pharmaceutical areas. Can you say anything on that or is there any analysis?
I think these are huge concerns: one, the cost to our health care system, and two, the possibility of losing investment to the United States if we don't consider all three issues—those of Canada, the United States, and Europe—in terms of the pharmaceutical industry.